Terumo BCT, Inc. is a global medical technology company headquartered in Lakewood, Colorado, specialising in blood component collection, therapeutic apheresis, and cellular therapy technologies. The company operates across more than 130 countries with a workforce of over 8,000 associates, and functions as a subsidiary of Terumo Corporation (TSE: 4543), a Tokyo-based medical device group founded in 1921.
Its technical portfolio spans several distinct but related domains: apheresis systems used to treat conditions such as sickle cell disease, therapeutic plasma exchange, blood safety, and the engineering infrastructure underpinning modern cell therapy manufacturing. Key products include the Spectra Optia Apheresis System, deployed for therapeutic apheresis procedures, and the Quantum Flex Cell Expansion System, a platform supporting CAR-T therapy development and broader cellular therapy manufacturing workflows.
The engineering and technology challenges at Terumo BCT span embedded systems, hardware-software integration, bioprocessing instrumentation, and the software platforms that govern cell expansion and apheresis procedures. The company works across the full stack from device-level control systems to manufacturing-scale cellular therapy platforms, operating in a regulated medical device environment.
Beyond its product lines, the company runs community-facing programmes such as From the Heart, a global initiative focused on blood safety education, and maintains partnerships with organisations including The Leukemia & Lymphoma Society. Its work sits at the intersection of transfusion medicine, hematology, and the rapidly expanding field of cell and gene therapy.
